The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
Year: 2018
Type: review
Abstract: : Recent advancements in immuno-oncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy. Keywords: CAR T-cells, tisagenlecleucel, acute lymphoblastic leukemia, CD19, cancer immunotherapy, chimeric antigen receptor
DOI: 10.2147/tcrm.s146309
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
Funders: National Science Foundation, U.S. Department of Health and Human Services, American Association for Cancer Research, Entertainment Industry Foundation, University of Wisconsin Carbone Cancer Center, National Institutes of Health, Stand Up To Cancer, National Cancer Institute, Division of Chemical, Bioengineering, Environmental, and Transport Systems
Awards: G1332332826, Inhibiting STAT1 as a novel graft-versus-host/graft-versus-leukemia therapy, G1712026730, G4004214011, G4326653730, G5357747714, G5699023890, G6403035411, CAREER: Towards Synthetic Biology in Human Stem Cells, G8190402583, EAGER BIOMANUFACTURING: A Microscale Testbed to Assay and Manufacture CAR T-Cell Immunotherapies, G9000179532, G9000352744, UW Comprehensive Cancer Center Support, G932800439
OpenAlex ID: W2889157625